Home  /  Resource Library  /  Real world characteristics and outcome of patients treated with single agent ibrutinib for chronic lymphocytic leukemia in Spain (IBRORS-LLC Study)

Real world characteristics and outcome of patients treated with single agent ibrutinib for chronic lymphocytic leukemia in Spain (IBRORS-LLC Study)

Results of a study examining real world outcomes of ibrutinib for the first line treatment of CLL.